| Literature DB >> 35875113 |
Dan Wan1, Hongyuan Zhou1, Yutao Zhang1.
Abstract
Adenoid cystic carcinoma (ACC) of the breast (breast ACC) is a rare tumor, especially in men, with only 17 cases reported in the literature. Owing to this rarity, male breast ACC is susceptible to missed or incorrect diagnoses, and data on treatment options and prognosis is also scarce. Herein, we report a case of a male patient with primary breast ACC and performed a detailed clinicopathological analysis of the 17 cases reported in the literature. A 38-year-old Chinese man patient developed right-sided breast nipple retraction in 2013 and presented to our hospital in 2015 with a palpable mass in the right breast for four days. B-scan ultrasound indicated the presence of a solid space-occupying lesion in the right breast. Breast Imaging Reporting and Data System (BI-RADS) classified the lesion as category 4B, and mammography showed a right breast nodule classified as BI-RADS 4C. Modified radical mastectomy for breast cancer was performed on the right breast. Microscopic examination of the excised tissue revealed diffuse tumor invasion of the subcutaneous fibers and adipose tissue, with tumor cells arranged in cribriform, tubular, and microcystic patterns. Immunohistochemical staining indicated that the glandular epithelial cells were positive for CD117, CK7, and Ki67 (approximately 30%) and negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, while the myoepithelial/basal cells were positive for P63, CK5/6 and S-100. Moreover, basement membrane materials were positive for collagen type IV. Molecular pathology analysis by fluorescence in situ hybridization revealed that the tumor was negative for MYB rearrangements. The patient was followed up for 82 months with no tumor recurrence or metastasis. According to the current literature, mastectomies have a better prognosis than lumpectomy. Accurately identifying the diagnosis of male breast ACC and considering the surgery of mastectomy may be the key factors for patients to obtain a good prognosis based on the microscopic characteristics of the tumor.Entities:
Keywords: MYB; adenoid cystic carcinoma; differential diagnosis; immunohistochemistry; male breast cancer
Year: 2022 PMID: 35875113 PMCID: PMC9300960 DOI: 10.3389/fonc.2022.905997
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Histopathology of male breast adenoid cystic carcinoma (Hematoxylin and eosin [H&E] stain). (A) Microscopic examination of the excised tissue revealed diffuse tumor invasion of the subcutaneous fibers and adipose tissue. (B) Cribriform patterns and basement membrane materials around tumor nest. (C) Cribriform patterns and the cavities contain mucus secretion. (D) Tubular pattern and the cavities contain mucus secretion. (E) Solid patterns. (F) Microcystic patterns. (G) Neural invasion. (H) Adipose invasion. [A: 40× magnification; B–H: 400× magnification].
Figure 2Immunohistochemical staining and MYB gene detection. (A) Epithelial cells were CD117-positive. (B) Epithelial cells were CK7-positive. (C) Basal cells were CK5/6-positive. (D) P63 highlighted intact myoepithelial cells around the acini. (E) ER was negative. (F) PR was negative. (G) Basement membrane materials were highlighted by collagen type IV staining. (H) Molecular pathology analysis by fluorescence in situ hybridization (FISH) revealed that the tumor was negative for MYB rearrangements. [(A–G) immunohistochemical staining, 400× magnification; (H) FISH, 1000× magnification]. ER, estrogen receptor; PR, progesterone receptor.
Clinical features of reported cases of breast adenoid cystic carcinoma in male patients.
| No. | Year | Age (years) | Side | Size (cm) | Axillary lymphnode | Treatment | Genetic testing | Follow-up |
|---|---|---|---|---|---|---|---|---|
|
| 1970 | 37 | NM | NM | NM | LE | NM | Recurrence at 5 and 7 years |
|
| 1973 | 78 | R | 3.5 | – | MRM+ALND | NM | Lung metastasis at 9 months |
|
| 1974 | 60 | L | NM | - | SM | NM | NM |
|
| 1977 | 21 | L | NM | – | SM | NM | Asymptomatic at 24 months |
|
| 1991 | 13 | R | 3.8 | - | SM | NM | Asymptomatic at 30 months |
|
| 2006 | 80 | R | 4 | +,1/10 | SM +ALND | NM | Asymptomatic at 60 months |
|
| 2006 | 82 | L | NM | +,3/5 | MRM+ALND | NM | Recurrence at 24 months |
|
| 2012 | 20 | R | 2.1 | – | SM+SNB | NM | NM |
|
| 2012 | 60 | L | 1.3 | - | RM | NM | Asymptomatic at 24 months |
|
| 2013 | 41 | L | 1.7 | + | NM | NM | Bone and lung metastasis |
|
| 2015 | 19 | R | 3.0 | - | RM+ALND | NM | Asymptomatic at 67 months |
|
| 2017 | 42 | L | 4.0 | – | MRM+ALND | NM | NM |
|
| 2019 | 21 | L | 5.0 | - | SM + SNB | NM | Asymptomatic at 12 months |
|
| 2019 | 44 | R | 1.2 | – | MRM + ALND | NM | Asymptomatic at 26 months |
|
| 2020 | 60 | R | 2.1 | NM | LE | NM | Lung metastasis |
|
| 2020 | 27 | L | 1.5 | – | MRM | MYB+ | Asymptomatic at 4 months |
|
| 2021 | 24 | L | 1.3 | - | MRM + ALND | NM | Asymptomatic at 28 months |
|
| 2022 | 37 | R | 1.5 | – | MRM + ALND | MYB- | Asymptomatic at 82 months |
NM, not mentioned; R, right; L, left; +, positive axillary lymph node, -, negative axillary lymph node; LE, lumpectomy; MRM, modified radical mastectomy; ALND, axillary lymph node dissection; SM, simple mastectomy; SNB, sentinel node biopsy; RM, radical mastectomy.